22 Penis cancer

Penis cancer

14

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 15/07/2022

15. REFERENCES

1. Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009 Apr;27(2):141-150. 2. Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 2000(205):189-93. 3. Maden C, Sherman KJ, Beckmann AM, Hislop TG, Teh CZ, Ashley RL, et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993 Jan 6;85(1):19-24. 4. Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P. Relationship between human papillomavirus and penile cancer-implications for prevention and treatment. Transl Androl Urol 2017 Oct;6(5):791-802. 5. Anic GM, Giuliano AR. Genital HPV infection and related lesions inmen. Prev Med 2011 Oct;53 Suppl 1:S36-41. 6. Opjordsmoen S, Fossa SD. Quality of life in patients treated for penile cancer. A follow-up study. Br J Urol 1994 Nov;74(5):652-7. 7. Opjordsmoen S, Waehre H, Aass N, Fossa SD. Sexuality in patients treated for penile cancer: patients' experience and doctors' judgement. Br J Urol 1994 May;73(5):554-60. 8. Djajadiningrat RS, Jordanova ES, Kroon BK, vanWerkhoven E, de Jong J, Pronk DT, et al. Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome. J Urol 2015 Feb;193(2):526-531. 9. Rubin MA, Kleter B, Zhou M, Ayala G, Cubilla AL, Quint WG, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 2001 Oct;159(4):1211-8. 10. Cubilla AL, Velazquez EF, Amin MB, Epstein J, Berney DM, Corbishley CM, et al. The World Health Organisation 2016 classification of penile carcinomas: a review and update from the International Society of Urological Pathology expert-driven recommendations. Histopathology 2018 May;72(6):893-904. 11. Sand FL, Rasmussen CL, FrederiksenMH, Andersen KK, Kjaer SK. Prognostic Significance of HPV and p16 Status in Men Diagnosed with Penile Cancer: A Systematic Review andMeta-analysis. Cancer Epidemiol Biomarkers Prev 2018 Oct;27(10):1123-1132. 12. De BaccoMW, Carvalhal GF, MacGregor B, Marcal JMB, Wagner MB, Sonpavde GP, et al. PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region. Clin Genitourin Cancer 2020 Jun;18(3):e254-e259. 13. Davidsson S, Carlsson J, Giunchi F, Harlow A, Kirrander P, Rider J, et al. PD- L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes. Eur Urol Oncol 2019 Mar;2(2):214-221. 14. Escande A, Haie-Meder C, Mazeron R, Maroun P, Cavalcanti A, de Crevoisier R, et al. Brachytherapy for Conservative Treatment of Invasive Penile Carcinoma: Prognostic Factors and Long-Term Analysis of Outcome. Int J Radiat Oncol Biol Phys 2017 Nov 1;99(3):563-570. 15. Martz N, Benziane-Ouaritini N, Gautier M, Brenot-Rossi I, Montagne L, Salem N, et al. Brachytherapy for oligometastatic prostate cancer to the penis. J Contemp Brachytherapy 2021 Oct;13(5):593-597. 16. Crook JM, Haie-Meder C, Demanes DJ, Mazeron JJ, Martinez AA, Rivard MJ. American Brachytherapy Society- (ABS-GEC-ESTRO) consensus statement for penile brachytherapy. Brachytherapy 2013 May-Jun;12(3):191-198. 17. Crook J, Jezioranski J, Cygler JE. Penile brachytherapy: technical aspects and postimplant issues. Brachytherapy 2010 Apr-Jun;9(2):151-158. 18. D'Alimonte L, Ravi A, Helou J, MorrisonD, Mendez LC, EastonH, et al. Optimized penile surface mold brachytherapy using latest stereolithography techniques: A single-institution experience. Brachytherapy 2019 May - Jun;18(3):348-352. 19. Marban M, Crook J, Keyes M, Dubash R, Batchelar D. High-dose-rate brachytherapy for localized penile cancer: Evolution of a technique. Brachytherapy 2020 Mar - Apr;19(2):201-209. 20. Pierquin B, Chassagne D, Wilson F. Modern Brachytherapy. NY: Masoom Pub; 1987. 21. Achkari S, Bourdais R, Sun R, Kumar T, K,M., Felefly T, et al. Dose-volume predictors of distal urethral toxicity after PDR brachytehrapy for penile cancer. Radiother Oncol 2020(https://www.estro.org/Congresses/ESTRO-2020/462/ clinicaltrack-urology-non-prostate/1367/). 22. Crook JM, Jezioranski J, Grimard L, Esche B, Pond G. Penile Brachytherapy: Results for 49 patients. Int J Radiat Oncol Biol Phys 2005 Jun 1;62(2):460-467. 23. Sharma DN, Joshi NP, Gandhi AK, Haresh KP, Gupta S, Julka PK, et al. High- dose-rate interstitial brachytherapy for T1-T2-stage penile carcinoma: short-term results. Brachytherapy 2014 Sep-Oct;13(5):481-487.

24. Pohankova D, Sirak I, Kasaova L, Grepl J, Paluska P, Louda M, et al. High-Dose Rate Brachyther-apy in the Treatment of Early Stages of Penile Carcinoma. Klin Onkol Winter 2019;32(1):52-57. 25. Kellas-Sleczka S, Bialas B, Fijalkowski M, Wojcieszek P, SzlagM, Cholewka A, et al. Nineteen-year single-center experience in 76 patients with penile cancer treated with high-dose-rate brachytherapy. Brachytherapy 2019 Jul - Aug;18(4):493-502. 26. Rouscoff Y, Falk AT, Durand M, Gal J, Chand ME, Gautier M, et al. High-dose rate brachytherapy in localized penile cancer: short-term clinical outcome analysis. Radiat Oncol 2014 Jun 19;9:142-717X-9-142. 27. Chaudhary AJ, Ghosh S, Bhalavat RL, Kulkarni JN, Sequeira BV. Interstitial brachytherapy in carcinoma of the penis. Strahlenther Onkol 1999 Jan;175(1):17- 20. 28. Crook J, Ma C, Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World J Urol 2009;27(2):189. 29. Delannes M, Malavaud B, Douchez J, Bonnet J, Daly NJ. Iridium-192 interstitial therapy for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys 1992;24(3):479-83. 30. Delaunay B, Soh PN, Delannes M, Riou O, Malavaud B, Moreno F, et al. Brachytherapy for penile cancer: Efficacy and impact on sexual function. Brachytherapy 2013 Jul 26. 31. Kiltie AE, Elwell C, Close HJ, Ash DV. Iridium-192 implantation for node- negative carcinoma of the penis: the Cookridge Hospital experience. Clin Oncol (R Coll Radiol) 2000;12(1):25-31. 32. Mazeron JJ, Langlois D, Lobo PA, Huart JA, Calitchi E, Lusinchi A, et al. Interstitial radiation therapy for carcinoma of the penis using iridium 192 wires: the Henri Mondor experience (1970-1979). Int J Radiat Oncol Biol Phys 1984 Oct;10(10):1891-5. 33. Pimenta A, Gutierrez C, Mosquera D, Pera J, Martinez E, Londres B, et al. Penile brachytherapy-Retrospective review of a single institution. Brachytherapy 2015 Jul-Aug;14(4):525-530. 34. Rozan R, Albuisson E, Giraud B, Donnarieix D, Delannes M, Pigneux J, et al. Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiother Oncol 1995 Aug;36(2):83-93. 35. Soria JC, Fizazi K, Piron D, Kramar A, Gerbaulet A, Haie-Meder C, et al. Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy. Ann Oncol 1997 Nov;8(11):1089-98. 36. Martz N, Bodokh Y, Gautier M, Thamphya B, Schiappa R, Lam Cham Kee D, et al. High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis. Clin Transl Radiat Oncol 2021 Jan 17;27:89-95. 37. Gomez-Iturriaga A, Crook J, EvansW, Saibishkumar EP, Jezioranski J.The efficacy of hyperbaric oxygen therapy in the treatment of medically refractory soft tissue necrosis after penile brachytherapy. Brachytherapy 2011 Nov;10(6):491-497. 38. Gambachidze D, Lebacle C, Maroun P, Escande A, Bossi A, Blanchard P, et al. Long-term evaluation of urinary, sexual, and quality of life outcomes after brachytherapy for penile carcinoma. Brachytherapy 2018 Jan - Feb;17(1):221-226.

ACKNOWLEDGEMENTS The authors of this chapter are much indebted to Alain Gerbaulet, author of the original version of the chapter on Penis Cancer in the first edition of the GEC-ESTRO Handbook of Brachytherapy 2002.

AUTHORS

Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia, BC Cancer Kelowna Canada Cyrus Chargari MD PhD Professor of medicine - Radiation Oncology Gustave Roussy Cancer Campus France